408 related articles for article (PubMed ID: 31050917)
1. Anacardic acid inhibits RANKL-induced osteoclastogenesis
Zhao K; Jia Y; Peng J; Pang C; Zhang T; Han W; Jiang J; Lu X; Zhu J; Qian Y
FASEB J; 2019 Aug; 33(8):9100-9115. PubMed ID: 31050917
[TBL] [Abstract][Full Text] [Related]
2. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
4. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
5. Cumambrin A prevents OVX-induced osteoporosis
Zhou L; Liu Q; Hong G; Song F; Zhao J; Yuan J; Xu J; Tan RX; Tickner J; Gu Q; Xu J
FASEB J; 2019 Jun; 33(6):6726-6735. PubMed ID: 30807230
[TBL] [Abstract][Full Text] [Related]
6. Cyanidin Chloride inhibits ovariectomy-induced osteoporosis by suppressing RANKL-mediated osteoclastogenesis and associated signaling pathways.
Cheng J; Zhou L; Liu Q; Tickner J; Tan Z; Li X; Liu M; Lin X; Wang T; Pavlos NJ; Zhao J; Xu J
J Cell Physiol; 2018 Mar; 233(3):2502-2512. PubMed ID: 28771720
[TBL] [Abstract][Full Text] [Related]
7. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M
Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431
[TBL] [Abstract][Full Text] [Related]
8. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
9. Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis.
Chen X; Zhi X; Pan P; Cui J; Cao L; Weng W; Zhou Q; Wang L; Zhai X; Zhao Q; Hu H; Huang B; Su J
FASEB J; 2017 Nov; 31(11):4855-4865. PubMed ID: 28739641
[TBL] [Abstract][Full Text] [Related]
10. Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways.
Wang T; Liu Q; Zhou L; Yuan JB; Lin X; Zeng R; Liang X; Zhao J; Xu J
Int J Mol Sci; 2015 Nov; 16(11):27470-81. PubMed ID: 26593901
[TBL] [Abstract][Full Text] [Related]
11. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
12. Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.
Zhu M; Liu H; Sun K; Liu J; Mou Y; Qi D; Zhou C; Abudunaibi M; Tasiken B; Li J; Cheng H; Huang H
Biomed Pharmacother; 2020 Mar; 123():109769. PubMed ID: 31846839
[TBL] [Abstract][Full Text] [Related]
13. α-Linolenic Acid Inhibits Receptor Activator of NF-κB Ligand Induced (RANKL-Induced) Osteoclastogenesis and Prevents Inflammatory Bone Loss via Downregulation of Nuclear Factor-KappaB-Inducible Nitric Oxide Synthases (NF-κB-iNOS) Signaling Pathways.
Song J; Jing Z; Hu W; Yu J; Cui X
Med Sci Monit; 2017 Oct; 23():5056-5069. PubMed ID: 29061958
[TBL] [Abstract][Full Text] [Related]
14. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
[TBL] [Abstract][Full Text] [Related]
15. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
van Heerden B; Kasonga A; Kruger MC; Coetzee M
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
[TBL] [Abstract][Full Text] [Related]
16. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
17. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
[TBL] [Abstract][Full Text] [Related]
18. Stachydrine prevents LPS-induced bone loss by inhibiting osteoclastogenesis via NF-κB and Akt signalling.
Meng J; Zhou C; Zhang W; Wang W; He B; Hu B; Jiang G; Wang Y; Hong J; Li S; He J; Yan S; Yan W
J Cell Mol Med; 2019 Oct; 23(10):6730-6743. PubMed ID: 31328430
[TBL] [Abstract][Full Text] [Related]
19. Bioactive iron oxide nanoparticles suppress osteoclastogenesis and ovariectomy-induced bone loss through regulating the TRAF6-p62-CYLD signaling complex.
Liu L; Jin R; Duan J; Yang L; Cai Z; Zhu W; Nie Y; He J; Xia C; Gong Q; Song B; Anderson JM; Ai H
Acta Biomater; 2020 Feb; 103():281-292. PubMed ID: 31866569
[TBL] [Abstract][Full Text] [Related]
20. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
